[go: up one dir, main page]

WO2002002743A3 - La famille nip3 de proteines - Google Patents

La famille nip3 de proteines Download PDF

Info

Publication number
WO2002002743A3
WO2002002743A3 PCT/US2001/021043 US0121043W WO0202743A3 WO 2002002743 A3 WO2002002743 A3 WO 2002002743A3 US 0121043 W US0121043 W US 0121043W WO 0202743 A3 WO0202743 A3 WO 0202743A3
Authority
WO
WIPO (PCT)
Prior art keywords
bnip3
necrosis
protein
nip
promoter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/021043
Other languages
English (en)
Other versions
WO2002002743A2 (fr
Inventor
Kenneth I Kohn
Arnold H Di Greenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Manitoba
Original Assignee
University of Manitoba
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Manitoba filed Critical University of Manitoba
Priority to AU2001271767A priority Critical patent/AU2001271767A1/en
Priority to CA002413250A priority patent/CA2413250A1/fr
Priority to EP01950808A priority patent/EP1299127A2/fr
Publication of WO2002002743A2 publication Critical patent/WO2002002743A2/fr
Publication of WO2002002743A3 publication Critical patent/WO2002002743A3/fr
Priority to US10/290,461 priority patent/US7452869B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne une protéine BNIP3 isolée et purifiée. L'invention concerne également une méthode induisant une nécrose dans des cellules par transfection d'une cellule avec une protéine BNIP3. L'invention concerne aussi une méthode induisant une nécrose dans des cellules par création d'un transgène surexprimant le gène de la protéine BNIP3. L'invention a également trait à un animal transgénique et sa descendance ayant un facteur d'expression constitué essentiellement d'une protéine BNIP3 choisie dans le groupe comprenant essentiellement Seq.ID 1 et 2. L'invention concerne également un vecteur destiné à être utilisé dans le traitement d'une maladie comportant BNIP3 ou DN NIP et un promoteur, de même qu'une thérapie génique comportant une BNIP3 ou DN NIP codant l'ADN ainsi qu'un promoteur, ladite thérapie génique étant utilisée pour induire une nécrose ou inhiber une nécrose.
PCT/US2001/021043 2000-06-30 2001-06-29 La famille nip3 de proteines Ceased WO2002002743A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2001271767A AU2001271767A1 (en) 2000-06-30 2001-06-29 The nip3 family of proteins
CA002413250A CA2413250A1 (fr) 2000-06-30 2001-06-29 La famille nip3 de proteines
EP01950808A EP1299127A2 (fr) 2000-06-30 2001-06-29 La famille nip3 de proteines
US10/290,461 US7452869B2 (en) 2000-06-30 2002-11-08 NIP3 family of proteins

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US21564300P 2000-06-30 2000-06-30
US60/215,643 2000-06-30
US21955400P 2000-07-20 2000-07-20
US60/219,554 2000-07-20

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/290,461 Continuation-In-Part US7452869B2 (en) 2000-06-30 2002-11-08 NIP3 family of proteins

Publications (2)

Publication Number Publication Date
WO2002002743A2 WO2002002743A2 (fr) 2002-01-10
WO2002002743A3 true WO2002002743A3 (fr) 2002-05-16

Family

ID=26910247

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/021043 Ceased WO2002002743A2 (fr) 2000-06-30 2001-06-29 La famille nip3 de proteines

Country Status (4)

Country Link
EP (1) EP1299127A2 (fr)
AU (1) AU2001271767A1 (fr)
CA (1) CA2413250A1 (fr)
WO (1) WO2002002743A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003256636A1 (en) * 2002-07-22 2004-02-09 University Of Miami Preventing ischemia-induced cell damage
WO2023079141A2 (fr) 2021-11-05 2023-05-11 Tienush Rassaf Amélioration et traitement de lésions d'infarctus

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
TSUNODA ET AL.: "Effects of wild-type and mutated p53 and Id proteins on the induction of apoptosis by adenovirus E1A, c-Myc, Bax and Nip3 in p53 null mouse cerebellum cells", BIOCHEM. BIOPHYS. RES. COMM., vol. 255, 1999, pages 722 - 730, XP002908157 *
VANDE VELDE ET AL.: "BNIP3 and genetic control of necrosis-like cell death through the mitochondrial permeability transition pore", MOLECULAR AND CELLULAR BIOLOGY, vol. 20, no. 15, August 2000 (2000-08-01), pages 5454 - 5468, XP002908158 *

Also Published As

Publication number Publication date
AU2001271767A1 (en) 2002-01-14
EP1299127A2 (fr) 2003-04-09
WO2002002743A2 (fr) 2002-01-10
CA2413250A1 (fr) 2002-01-10

Similar Documents

Publication Publication Date Title
Gudmundsson et al. Structure of the gene for porcine peptide antibiotic PR-39, a cathelin gene family member: comparative mapping of the locus for the human peptide antibiotic FALL-39.
US6448391B1 (en) Ubiquitin-lytic peptide gene promoter
DE59209981D1 (de) Rekombinantes core-streptavidin
WO2001072976A3 (fr) 32142, 21481, 25964, 21686, nouvelles molecules deshydrogenases humaines et utilisations
WO2000073478A3 (fr) Vecteurs adenoviraux recombinants pour l'infection specifique de cellules, l'integration de genomes et l'expression de proteines fibreuses chimeriques
IL87041A0 (en) Induction of virus resistance in plants,recombinant dna molecules for use therein,their preparation and vectors and host cells comprising them
WO2001090323A3 (fr) Nouveau membre de la famille des lipoxydases humaines appele 46638, et ses utilisations
US20080009447A1 (en) Modulating cytokine or hormone signalling in an animal comprising up-regulating the expression of SOCS sequence in the animal
WO2002002743A3 (fr) La famille nip3 de proteines
ATE312184T1 (de) Promotor zur regulierung von fremdgenexpression
WO2002002760A3 (fr) 25869, nouvelle carboxylesterase humaine et ses utilisations
WO2003048325A3 (fr) Sequences nucleotidiques de promoteurs de la beta-actine et de l'actine issus de crevettes et leur utilisation en genie genetique
CA2404471A1 (fr) Construction capable de liberation en forme circulaire fermee a partir d'une sequence nucleotidique plus grande permettant l'expression specifique du milieu et/ou l'expression a regulation de developpement de sequences genetiques selectionnees
WO1999027093A3 (fr) Famille nip3 de proteines
CA2310726A1 (fr) Promoteur pour embryons et semis
WO2002006485A3 (fr) 47885, une nouvelle enzyme activant l'ubiquitine humaine et ses applications
WO2002044357A3 (fr) Procedes d'utilisation de 18903 dans le traitement de la douleur et des troubles lies a la douleur
WO2002000863A3 (fr) 32140, nouvelle deshydrogenase de l'aldehyde humaine et utilisations correspondantes
WO2002016588A3 (fr) A 15985, nouveau membre humain de la famille des proteines kinases serines/threonines, et ses utilisations
WO2001090145A3 (fr) 57805, nouvel element de la famille des cadherines humaines et utilisations correspondantes
WO2002040674A3 (fr) 67118, 67067 et 62092, proteines humaines et leurs procedes d'utilisation
WO2002024911A3 (fr) Le 63760, nouveau transporteur humain et ses utilisations
WO2002029037A3 (fr) 57800, nouvelle cadherine humaine et ses applications
WO1998014218A1 (fr) MAMMIFERES ET CELLULES POSSEDANT UNE DISRUPTION HOMOZYGOTE DANS LE GENE RNase L ET PROCEDES ASSOCIES
WO2001074854A3 (fr) Le 32449, nouveau transporteur humain et ses utilisations

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 10290461

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 2413250

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001950808

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001950808

Country of ref document: EP

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWW Wipo information: withdrawn in national office

Ref document number: 2001950808

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP